PMID- 36284362
OWN - NLM
STAT- MEDLINE
DCOM- 20221027
LR  - 20231213
IS  - 1465-542X (Electronic)
IS  - 1465-5411 (Print)
IS  - 1465-5411 (Linking)
VI  - 24
IP  - 1
DP  - 2022 Oct 25
TI  - Matrix Gla protein (MGP), GATA3, and TRPS1: a novel diagnostic panel to determine 
      breast origin.
PG  - 70
LID - 10.1186/s13058-022-01569-1 [doi]
LID - 70
AB  - BACKGROUND: Metastatic breast carcinoma is commonly considered during 
      differential diagnosis when metastatic disease is detected in females. In 
      addition to the tumor morphology and documented clinical history, sensitive and 
      specific immunohistochemical (IHC) markers such as GCDFP-15, mammaglobin, and 
      GATA3 are helpful for determining breast origin. However, these markers are 
      reported to show lower sensitivity in certain subtypes, such as triple-negative 
      breast cancer (TNBC). MATERIALS AND METHODS: Using bioinformatics analyses, we 
      identified a potential diagnostic panel to determine breast origin: matrix Gla 
      protein (MGP), transcriptional repressor GATA binding 1 (TRPS1), and GATA-binding 
      protein 3 (GATA3). We compared MGP, TRPS1, and GATA3 expression in different 
      subtypes of breast carcinoma of (n = 1201) using IHC. As a newly identified 
      marker, MGP expression was also evaluated in solid tumors (n = 2384) and normal 
      tissues (n = 1351) from different organs. RESULTS: MGP and TRPS1 had comparable 
      positive expression in HER2-positive (91.2% vs. 92.0%, p = 0.79) and TNBC 
      subtypes (87.3% vs. 91.2%, p = 0.18). GATA3 expression was lower than MGP 
      (p < 0.001) or TRPS1 (p < 0.001), especially in HER2-positive (77.0%, p < 0.001) 
      and TNBC (43.3%, p < 0.001) subtypes. TRPS1 had the highest positivity rate 
      (97.9%) in metaplastic TNBCs, followed by MGP (88.6%), while only 47.1% of 
      metaplastic TNBCs were positive for GATA3. When using MGP, GATA3, and TRPS1 as a 
      novel IHC panel, 93.0% of breast carcinomas were positive for at least two 
      markers, and only 9 cases were negative for all three markers. MGP was detected 
      in 36 cases (3.0%) that were negative for both GATA3 and TRPS1. MGP showed 
      mild-to-moderate positive expression in normal hepatocytes, renal tubules, as 
      well as 31.1% (99/318) of hepatocellular carcinomas. Rare cases (0.6-5%) had 
      focal MGP expression in renal, ovarian, lung, urothelial, and 
      cholangiocarcinomas. CONCLUSIONS: Our findings suggest that MGP is a newly 
      identified sensitive IHC marker to support breast origin. MGP, TRPS1, and GATA3 
      could be applied as a reliable diagnostic panel to determine breast origin in 
      clinical practice.
CI  - (c) 2022. The Author(s).
FAU - Du, Tian
AU  - Du T
AD  - State Key Laboratory of Oncology in South China, Collaborative Innovation Center 
      for Cancer Medicine, Guangzhou, 510060, People's Republic of China.
AD  - Department of Breast Surgery, Sun Yat-Sen University Cancer Center, Guangzhou, 
      510060, People's Republic of China.
FAU - Pan, Lu
AU  - Pan L
AD  - State Key Laboratory of Oncology in South China, Collaborative Innovation Center 
      for Cancer Medicine, Guangzhou, 510060, People's Republic of China.
AD  - Department of Pathology, Sun Yat-Sen University Cancer Center, Guangzhou, 510060, 
      People's Republic of China.
FAU - Zheng, Chengyou
AU  - Zheng C
AD  - State Key Laboratory of Oncology in South China, Collaborative Innovation Center 
      for Cancer Medicine, Guangzhou, 510060, People's Republic of China.
AD  - Department of Pathology, Sun Yat-Sen University Cancer Center, Guangzhou, 510060, 
      People's Republic of China.
FAU - Chen, Keming
AU  - Chen K
AD  - State Key Laboratory of Oncology in South China, Collaborative Innovation Center 
      for Cancer Medicine, Guangzhou, 510060, People's Republic of China.
AD  - Department of Pathology, Sun Yat-Sen University Cancer Center, Guangzhou, 510060, 
      People's Republic of China.
FAU - Yang, Yuanzhong
AU  - Yang Y
AD  - State Key Laboratory of Oncology in South China, Collaborative Innovation Center 
      for Cancer Medicine, Guangzhou, 510060, People's Republic of China.
AD  - Department of Pathology, Sun Yat-Sen University Cancer Center, Guangzhou, 510060, 
      People's Republic of China.
FAU - Chen, Jiewei
AU  - Chen J
AD  - State Key Laboratory of Oncology in South China, Collaborative Innovation Center 
      for Cancer Medicine, Guangzhou, 510060, People's Republic of China.
AD  - Department of Pathology, Sun Yat-Sen University Cancer Center, Guangzhou, 510060, 
      People's Republic of China.
FAU - Chao, Xue
AU  - Chao X
AD  - State Key Laboratory of Oncology in South China, Collaborative Innovation Center 
      for Cancer Medicine, Guangzhou, 510060, People's Republic of China.
AD  - Department of Pathology, Sun Yat-Sen University Cancer Center, Guangzhou, 510060, 
      People's Republic of China.
FAU - Li, Mei
AU  - Li M
AD  - State Key Laboratory of Oncology in South China, Collaborative Innovation Center 
      for Cancer Medicine, Guangzhou, 510060, People's Republic of China.
AD  - Department of Pathology, Sun Yat-Sen University Cancer Center, Guangzhou, 510060, 
      People's Republic of China.
FAU - Lu, Jiabin
AU  - Lu J
AD  - State Key Laboratory of Oncology in South China, Collaborative Innovation Center 
      for Cancer Medicine, Guangzhou, 510060, People's Republic of China.
AD  - Department of Pathology, Sun Yat-Sen University Cancer Center, Guangzhou, 510060, 
      People's Republic of China.
FAU - Luo, Rongzhen
AU  - Luo R
AD  - State Key Laboratory of Oncology in South China, Collaborative Innovation Center 
      for Cancer Medicine, Guangzhou, 510060, People's Republic of China.
AD  - Department of Pathology, Sun Yat-Sen University Cancer Center, Guangzhou, 510060, 
      People's Republic of China.
FAU - Zhang, Jinhui
AU  - Zhang J
AD  - State Key Laboratory of Oncology in South China, Collaborative Innovation Center 
      for Cancer Medicine, Guangzhou, 510060, People's Republic of China.
AD  - Department of Pathology, Sun Yat-Sen University Cancer Center, Guangzhou, 510060, 
      People's Republic of China.
FAU - Wu, Yu
AU  - Wu Y
AD  - State Key Laboratory of Oncology in South China, Collaborative Innovation Center 
      for Cancer Medicine, Guangzhou, 510060, People's Republic of China.
AD  - Department of Pathology, Sun Yat-Sen University Cancer Center, Guangzhou, 510060, 
      People's Republic of China.
FAU - He, Jiehua
AU  - He J
AD  - State Key Laboratory of Oncology in South China, Collaborative Innovation Center 
      for Cancer Medicine, Guangzhou, 510060, People's Republic of China. 
      hejh@sysucc.org.cn.
AD  - Department of Pathology, Sun Yat-Sen University Cancer Center, Guangzhou, 510060, 
      People's Republic of China. hejh@sysucc.org.cn.
FAU - Jiang, Dongping
AU  - Jiang D
AD  - State Key Laboratory of Oncology in South China, Collaborative Innovation Center 
      for Cancer Medicine, Guangzhou, 510060, People's Republic of China. 
      jiangdp@sysucc.org.cn.
AD  - Department of Medical Imaging, Sun Yat-Sen University Cancer Center, Guangzhou, 
      510060, People's Republic of China. jiangdp@sysucc.org.cn.
FAU - Sun, Peng
AU  - Sun P
AD  - State Key Laboratory of Oncology in South China, Collaborative Innovation Center 
      for Cancer Medicine, Guangzhou, 510060, People's Republic of China. 
      sunpeng1@sysucc.org.cn.
AD  - Department of Pathology, Sun Yat-Sen University Cancer Center, Guangzhou, 510060, 
      People's Republic of China. sunpeng1@sysucc.org.cn.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20221025
PL  - England
TA  - Breast Cancer Res
JT  - Breast cancer research : BCR
JID - 100927353
RN  - 0 (Biomarkers, Tumor)
RN  - 0 (GATA3 Transcription Factor)
RN  - 0 (Mammaglobin A)
RN  - 0 (Calcium-Binding Proteins)
RN  - 0 (GATA3 protein, human)
RN  - 0 (TRPS1 protein, human)
RN  - 0 (Repressor Proteins)
RN  - Trichorhinophalangeal Syndrome, Type I
SB  - IM
MH  - Female
MH  - Humans
MH  - *Triple Negative Breast Neoplasms/diagnosis/genetics/metabolism
MH  - *Breast Neoplasms/diagnosis/genetics/pathology
MH  - Biomarkers, Tumor/metabolism
MH  - GATA3 Transcription Factor/genetics
MH  - Mammaglobin A/analysis/metabolism
MH  - Calcium-Binding Proteins
MH  - Repressor Proteins/genetics/metabolism
MH  - Matrix Gla Protein
PMC - PMC9598034
OTO - NOTNLM
OT  - Breast carcinoma
OT  - GATA3
OT  - Immunohistochemical
OT  - MGP
OT  - TRPS1
COIS- The authors declare that they have no competing interests.
EDAT- 2022/10/27 06:00
MHDA- 2022/10/28 06:00
PMCR- 2022/10/25
CRDT- 2022/10/26 00:32
PHST- 2022/05/13 00:00 [received]
PHST- 2022/10/18 00:00 [accepted]
PHST- 2022/10/26 00:32 [entrez]
PHST- 2022/10/27 06:00 [pubmed]
PHST- 2022/10/28 06:00 [medline]
PHST- 2022/10/25 00:00 [pmc-release]
AID - 10.1186/s13058-022-01569-1 [pii]
AID - 1569 [pii]
AID - 10.1186/s13058-022-01569-1 [doi]
PST - epublish
SO  - Breast Cancer Res. 2022 Oct 25;24(1):70. doi: 10.1186/s13058-022-01569-1.